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Abstract Recognition and elimination of tumor cells by the immune system is crucial for limiting
tumor growth. Natural killer (NK) cells become activated when the receptor NKG2D is engaged by
ligands that are frequently upregulated in primary tumors and on cancer cell lines. However, the
molecular mechanisms driving NKG2D ligand expression on tumor cells are not well defined. Using a
forward genetic screen in a tumor-derived human cell line, we identified several novel factors
supporting expression of the NKG2D ligand ULBP1. Our results show stepwise contributions of
independent pathways working at multiple stages of ULBP1 biogenesis. Deeper investigation of
selected hits from the screen showed that the transcription factor ATF4 drives ULBP1 gene
expression in cancer cell lines, while the RNA-binding protein RBM4 supports ULBP1 expression by
suppressing a novel alternatively spliced isoform of ULBP1 mRNA. These findings offer insight into
the stress pathways that alert the immune system to danger.
DOI: 10.7554/eLife.08474.001
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Natural killer (NK) cells are lymphocytes of the innate immune system that play a critical role in limiting
tumor growth (Vivier et al., 2011; Marcus et al., 2014; Mittal et al., 2014). NK cell activation is
controlled by a balance of signals from activating and inhibitory receptors, which recognize cognate
ligands expressed by potential target cells (Vivier et al., 2011; Shifrin et al., 2014). One of the beststudied NK-activating receptors is NKG2D, which is also expressed on certain subsets of T cells
(Raulet, 2003). Engagement of NKG2D by its ligands displayed on a target cell membrane leads to
NK cell activation, cytokine secretion, and lysis of target cells, such as tumor cells.
NKG2D recognizes a family of ligands that are structurally similar to MHC Class I proteins. Humans
express up to eight NKG2D ligands (ULBP1-6, MICA, and MICB), and mice express 5–6 different ligands,
depending on the strain (RAE-1α-ε, H60a-c, and MULT1) (Raulet et al., 2013). Healthy cells typically do
not display NKG2D ligands on their surface and are thus poor targets for NKG2D-mediated lysis by NK
cells. However, cellular stresses associated with transformation, viral infection, or other danger to the
host cause the upregulation of NKG2D ligand expression (Raulet et al., 2013). Primary tumors and
cancer cell lines frequently express one or more NKG2D ligand, and NKG2D expression is important for
the control of tumors in vivo in models of spontaneous cancer (Guerra et al., 2008).
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eLife digest Cancer is caused by a series of mutations that result in uncontrolled cell growth and
division. Yet, the body’s immune system can often detect and destroy abnormal cells before they
cause tumors and disease. Natural killer cells are part of the immune system and have receptors on
their surface that allow them to tell the difference between healthy host cells and host cells that are
stressed or abnormal. Some of these receptors activate the natural killer cells when they bind to their
target molecules. Other receptors have the opposite effect and inhibit the natural killer cells.
Activation occurs when the signaling from the activating receptors is stronger than the signals from
the inhibitory receptors.
One of the well-studied activating receptors recognizes a number of proteins and molecules that
are produced by abnormal or tumor cells, including a protein called ULBP1. This protein is absent
from the surface of healthy cells but is found in abundance on tumor cells. However, it is still not clear
what drives tumor cells to produce ULBP1 (or other molecules) that are recognized by natural killer
cell receptors.
Now, Gowen et al. report on a genetic screen that has revealed numerous genes that regulate the
levels of ULBP1 in human cells. Many of these genes had independent effects that when added
together accounted for most of the ULBP1 present on the cell surface.
Gowen et al. then explored some of the ‘regulators’ encoded by these genes in more detail. One
called ATF4, which had previously been linked to stress responses, was shown to increase the
expression of the gene for ULBP1 in cancer cells. Another regulator called RBM4 instead acted in a
different way and at a later stage in ULBP1 production.
All together, these findings offer insight into the stress pathways that alert the immune system to
abnormal cells. The next challenge will be investigating how these pathways might be exploited for
cancer immunotherapy.
DOI: 10.7554/eLife.08474.002

Tumors arise despite the tumor-suppressive effects of the immune system, and some tumors show
evidence of adaptation to escape immune control (Schreiber et al., 2011). In the case of NKG2Dmediated tumor recognition, published results suggest that one mechanism of tumor immune
evasion is the loss or decreased expression of NKG2D ligands (Guerra et al., 2008; McGilvray et al.,
2009). In other cases, tumors progress despite sustained expression of NKG2D ligands (Vetter
et al., 2002; Guerra et al., 2008; McGilvray et al., 2009; Hilpert et al., 2012). The evidence as a
whole suggests that upregulation of NKG2D ligands on early stage tumor cells is part of a host
defense mechanism, but that the immune response subsequently applies selective pressure for
tumors that have either extinguished expression of NKG2D ligands or have activated immune
suppressive mechanisms (Raulet and Guerra, 2009). Therefore, identifying factors and pathways
that regulate NKG2D ligands will improve our understanding of the cellular properties used by
the immune system to define unwanted cells and will also help reveal how tumors evade the
corresponding immune responses.
Prior investigations have identified regulators of NKG2D ligands using a candidate approach based
on the roles of these regulators in known stress pathways. Such approaches have implicated the DNA
damage response pathway (Gasser et al., 2005), heat shock (Venkataraman et al., 2007; Nice et al.,
2009), hyperproliferation (Jung et al., 2012), and pattern recognition receptors (Hamerman et al.,
2004), among others, in the regulation of one or more NKG2D ligands. However, these pathways do
not account fully for expression of ligands in tumor cells, since inhibiting them may decrease ligand
expression but typically does not abrogate it. For example, the DNA damage response is active in
many cancer cells and tumor cell lines, but inhibiting that pathway only partially inhibits ligand
expression (Gasser et al., 2005; Gasser and Raulet, 2006; Soriani et al., 2014). Similarly,
hyperproliferation can drive NKG2D ligand expression, but blocking proliferation does not completely
eliminate NKG2D ligand expression by tumor cell lines (Jung et al., 2012). These findings suggest
that unidentified molecular cues in tumor cells also initiate the expression of NKG2D ligands, allowing
potentially dangerous tumor cells to be distinguished from normal cells. Identifying those cues,
especially for human NKG2D ligands, is important for understanding the biological regulation of
NKG2D ligands and devising approaches for immunotherapy based on that knowledge.
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To identify novel drivers of NKG2D ligand expression, we performed a genome-wide loss-ofexpression mutant screen in the tumor-derived human cell line HAP1 (Carette et al., 2009; Carette
et al., 2011) and used CRISPR/Cas9 gene targeting methodology for confirmation of the hits and
extension of the results. The results reveal previously unknown regulators for NKG2D ligands, provide
evidence for selectivity of the regulators for specific ligands, and support the cooperation of different
stress pathways in the regulation of one such ligand.

Results
A genome-wide screen to identify novel drivers of ULBP1 expression
Many tumors and cancer cell lines express multiple NKG2D ligands, possibly due to ongoing stress
responses associated with the transformed state (Raulet et al., 2013). To identify novel drivers of human
NKG2D ligand expression in transformed cells, we employed a retroviral gene-trap mutagenesis screen
using the near-haploid human cell line HAP1 (Figure 1) (Carette et al., 2009; Carette et al., 2011). Like
many cell lines, HAP1 cells express multiple NKG2D ligands (Figure 1—figure supplement 1). We
chose to screen for drivers of ULBP1 expression because it showed the brightest staining on HAP1 cells,
making it particularly amenable to our loss-of-expression screen. Following mutagenesis, we selected
for mutants with decreased expression of ULBP1 but intact expression of the unrelated GPI-anchored
protein CD55 (Figure 1A). Selection of CD55+ cells was used to reduce the fraction of selected cells that
had lost ULBP1 expression due to mutations that alter cell surface expression of all proteins or of all GPIlinked proteins. In the first round of selection, we depleted ULBP1high cells from the mutant cell
population using magnetic bead-based depletion of cells labeled with a ULBP1 antibody. After briefly
expanding the selected cells, we used flow cytometry to further select for ULBP1lowCD55+ cells.
Figure 1B shows ULBP1 and CD55 expression on WT and post-selection HAP1 cells.
We employed deep-sequencing to map and quantify the frequencies of independent insertion
sites of the retroviral gene-trap in selected cells and compared this with the landscape of insertions in
unselected control cells. Table 1 shows a selected ‘hit list’ of genes that were targeted significantly
more frequently in selected ULBP1lowCD55+ cells than in unselected cells. The ULBP1 gene itself was a
highly significant hit, providing a validation of this approach. Many genes encoding enzymes involved
in GPI synthesis were also represented despite the selection for CD55 expression; many of these were
removed from Table 1, for simplicity. The complete list of hits (p < 0.05) is shown in Supplementary
file 1, along with the analysis of all independent insertions mapped in the selected data set. Raw
sequencing data for the screen are available under NCBI Bioproject PRJNA284536, containing the
datasets for HAP1 gene trap control cells (Accession number SAMN03703230) and cells from the
ULBP1 screen (Accession number SAMN03703231). We chose hits for validation and follow-up
experiments based on their statistical ranking and expectations that the corresponding proteins play
roles in stress responses, protein biogenesis, or gene/mRNA regulation. The genes chosen encode
ATF4 (a stress-associated transcription factor), RBM4 (an RNA-binding protein), HSPA13 (a protein
chaperone), and SPCS1 and SPCS2, which are both non-catalytic subunits of the signal peptidase
complex.

Validation of hits using the CRISPR/Cas9 system and gene restoration
To confirm that selected genes from the screen regulate ULBP1, we employed the CRISPR/Cas9
mutagenesis system, targeting sites in the 5′ coding regions of each candidate gene in HAP1 cells
(Jinek et al., 2013; Mali et al., 2013). The ULBP1 gene was targeted for comparison. After HAP1 cells
were transiently transfected with plasmids encoding Cas9 and guide RNAs (sgRNAs) for each candidate
gene, a population of ULBP1low cells appeared that was absent in control transfected cells
(Figure 2—figure supplement 1). In each case, individual ULBP1low cells were sorted into 96-well
plates, and expanded clones were screened for mutations by PCR and sequencing. For further analysis,
we selected clones with insertions or deletions that resulted in frameshift mutations in each targeted
gene (Figure 2—figure supplement 2). Since the sites targeted were near the beginning of each
coding region and the cells are haploid, the frameshift mutations are expected to result in complete
loss-of-function of the corresponding proteins. Analysis of HAP1 cell lysates by Western blot confirmed
the loss-of-protein expression in ATF4, RBM4, and SPCS2 mutant cell lines (data not shown).
Cells with a ULBP1 mutation lacked cell surface ULBP1 staining altogether, as expected, whereas the
other mutations analyzed resulted in a partial (twofold to threefold) decrease in cell surface expression
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Figure 1. A genetic screen of a haploid human cell line to identify regulators of ULBP1 expression. (A) HAP1 cells
(∼108 cells) were transduced with a retroviral gene-trap vector. To enrich for mutant cells with decreased ULBP1
expression, we initially depleted ULBP1high cells by labeling cells with an anti-ULBP1 antibody followed by magnetic
bead-based cell depletion. Following a brief recovery and expansion of the cells, we used FACS to further enrich
ULBP1lowCD55+ cells. Deep-sequencing of genomic DNA from pre- and post-selection cells was used to map sites of
gene-trap insertions, and mutations enriched in ULBP1low cells were identified. (B) Flow cytometric analysis of WT
and post-selection HAP1 cells. Cells were stained for ULBP1 and CD55, an irrelevant GPI-linked protein.
DOI: 10.7554/eLife.08474.003
The following figure supplement is available for figure 1:
Figure supplement 1. Expression of NKG2D ligands on HAP1 cells.
DOI: 10.7554/eLife.08474.004

of ULBP1 (Figure 2A). The effect of each mutation was specific to ULBP1, as we found no change in cell
surface expression of other proteins, including four other NKG2D ligands (ULBP2, ULBP3, MICA, and
MICB), HLA Class I, the unrelated GPI-anchored protein CD59, or PVR and Nectin-2, the ligands for
DNAM-1, another NK cell-activating receptor (Figure 2B,C, Figure 2—figure supplement 3). The
minor changes in ULBP3 staining seen in Figure 2—figure supplement 3B were not consistently
observed across experiments. The finding that the mutations each affect only ULBP1 among the NKG2D
ligands tested supports the hypothesis that different NKG2D ligands are subject to distinct regulatory
processes. It was surprising that SPCS1 and SPCS2 mutations only impacted cell surface staining of
ULBP1 and not the six other membrane proteins tested, as we had expected that mutating components
of the signal peptidase complex would cause a more generalized defect in cell surface protein
expression (see ‘Discussion’). In all cases, ULBP1 expression on mutant lines could be restored by
re-expressing the gene of interest with a doxycycline-inducible lentiviral vector (Figure 2D). These
findings established that ATF4, RBM4, HSPA13, SPCS1, and SPCS2 each contribute partially to cell
surface display of ULBP1 in HAP1 cells in steady-state culture conditions.
Consistent with their presumptive roles in gene expression and/or splicing, ATF4 and RBM4 KO
cells each showed decreased amounts of canonically spliced ULBP1 mRNA commensurate with the
change in cell surface expression (Figure 2E). Consistent with their roles as chaperones and
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Table 1. Selected list of genes enriched for gene-trap insertions after selection of ULBP1lowCD55+ cells
Gene symbol

Function/Process

p-value

PIGW

GPI synthesis/anchoring

1.12E-196

PIGQ

GPI synthesis/anchoring

3.26E-155

PIGB

GPI synthesis/anchoring

2.38E-103

ULBP1

NKG2D ligand

2.65E-76

PIGO

GPI synthesis/anchoring

1.49E-65

RBM4

RNA-binding protein

1.29E-24

PIGV

GPI synthesis/anchoring

4.43E-23

SPCS1

Non-catalytic subunit of signal peptidase
complex

1.25E-15

PIGM

GPI synthesis/anchoring

6.06E-14

C1GALT1C1

Protein O-linked glycosylation

2.22E-13

SLC35A1

Golgi-localized CMP-sialic acid transporter

1.77E-12

ST3GAL2

Sialyltransferase

1.64E-11

SPCS2

Non-catalytic subunit of signal peptidase
complex

6.20E-09

HSPA13

Microsome-associated protein with
ATPase activity

1.24E-05

FLJ37453

Non-coding RNA

0.00115

SLC17A9*

Vesicular nucleotide transporter

0.00715

RPS25

Ribosomal protein

0.00715

ATF4

Stress-induced transcription factor

0.0206

PMM2

Oligosaccharide synthesis, protein
glycosylation

0.0234

NCRNA00167

Non-coding RNA

0.0363

CRNKL1*

Pre-mRNA splicing

0.0363

ICK

Intestinal cell kinase, MAPK-related

0.0363

TBC1D19

TBC domain-containing protein

0.0416

ZNF236

Zinc-finger protein

0.0496

The gene symbols of hits (p < 0.05) are shown with a brief description of known or predicted gene functions. A
p-value of enrichment was determined using Fisher’s exact test, followed by correction for the false discovery rate.
The list was manually curated to remove known genes that have occurred in several unrelated screens using the
same cells, perhaps indicating pleiotropic effects. For simplicity, a number of genes related to GPI biosynthesis and
anchoring were removed. Bold text indicates genes confirmed in this study to impact ULBP1 expression. Blue text
indicates genes involved in GPI biosynthesis and anchoring. Red text indicates genes involved in protein
glycosylation. Asterisks indicate two genes (SLC17A9 and CRNKL1) that, when targeted with CRISPR/Cas9, failed to
result in decreased ULBP1 expression.
DOI: 10.7554/eLife.08474.005

protein-processing components, HSPA13, SPCS1, and SPCS2 KO cells all showed WT amounts of
ULBP1 mRNA.

Stepwise regulation of ULBP1 expression
To assess whether the genes implicated in ULBP1 expression work independently or in common
pathways, we generated and analyzed double and triple-mutant cell lines. We generated ATF4/RBM4
double-mutant cells by targeting ATF4 in the RBM4 KO line, and triple-mutant cells by further
targeting either HSPA13 or SPCS2 in the double-mutant line. Notably, we observed stepwise
decreases in ULBP1 expression with each additional mutation, with triple-mutant cells showing up to a
20-fold reduction in ULBP1 expression compared to WT cells (Figure 3A). These data suggested that
the genes tested (with the likely exception of SPCS1 vs SPCS2) contribute largely independently to
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Figure 2. Decreased ULBP1 expression upon targeted mutation of screen hits. (A–C) Flow cytometric analysis of cell surface expression of ULBP1 (A), the
NKG2D ligand MICA (B), or pan-HLA Class I (C) on WT and mutant HAP1 cells. WT and mutant (KO) cells are represented as black and red histograms,
respectively. The shaded gray histogram represents isotype control staining. The blue trace in panel A shows staining of ULBP1 KO HAP1 cells and
matches isotype control staining. Data are representative of at least three independent experiments. (D) To restore expression of ULBP1 drivers, mutant
Figure 2. continued on next page
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Figure 2. Continued
cell lines were transduced with a doxycycline-inducible lentiviral vector containing the gene of interest. Cells were treated for 24 hr with doxycycline (Dox)
at a final concentration of 100 ng/ml for ATF4 and 1000 ng/ml for all other genes. After treatment, cells were analyzed by flow cytometry. Black histograms:
WT cells transduced with control vector, +Dox. Red histograms: mutant cells transduced with Dox-inducible gene of interest, −Dox. Blue histograms:
mutant cells transduced with Dox-inducible gene of interest, +Dox. The shaded gray histogram represents isotype control staining. Data are
representative of three independent experiments. (E) RT-qPCR analysis of canonically spliced ULBP1 mRNA expression levels in WT and mutant HAP1
cells. Expression levels were normalized to ACTB, GAPDH, and HPRT1 and are shown as mean ±SE. The data were analyzed by 1-way ANOVA with
Dunnet’s multiple comparisons test comparing all samples to WT. ***p < 0.001. Data are representative of three independent experiments. In one out of
three total experiments performed, the level of ULBP1 mRNA was significantly increased in the SPCS2 mutant compared to WT.
DOI: 10.7554/eLife.08474.006
The following figure supplements are available for figure 2:
Figure supplement 1. Mutagenesis of screen ’hits’ with the CRISPR/Cas9 system.
DOI: 10.7554/eLife.08474.007
Figure supplement 2. Sequences of CRISPR/Cas9 target sites in HAP1 cells.
DOI: 10.7554/eLife.08474.008
Figure supplement 3. Expression of additional NK cell ligands is unchanged on mutant HAP1 cells.
DOI: 10.7554/eLife.08474.009

steady-state ULBP1 expression in HAP1 cells and support a model in which constitutive NKG2D ligand
expression in cell lines is due, at least in some instances, to the contribution of several pathways that
act cumulatively. ATF4/RBM4 double mutants showed a larger decrease in canonically spliced ULBP1
mRNA than either single mutant, suggesting that ATF4 and RBM4 may act independently in
regulating the amounts of ULBP1 mRNA (Figure 3B). There were no greater decreases in ULBP1
mRNAs when mutations in either HSPA13 or SPCS2 were added to the double-mutant cells, as
expected if they act co-translationally or post-translationally.

ATF4 supports ULBP1 expression on multiple tumor-derived cell lines
Having validated several hits from our screen, we investigated the roles of ATF4 and RBM4 in
regulating ULBP1 expression. To address whether ATF4 regulates ULBP1 in other cell types, we
mutated ATF4 in the K-562 chronic myelogenous leukemia cell line and the Jurkat acute T-cell
leukemia cell line. ATF4 KO K-562 and Jurkat cells were generated using Cas9 and a pair of sgRNAs
that flank the ATF4 gene. The entire ATF4 gene was deleted in the resulting mutant lines, eliminating
the possibility of the mutant cells expressing a functional ATF4 protein fragment. HAP1 cells carrying a
similar deletion of ATF4 had an identical phenotype to the ATF4 frameshift mutant line described
above (data not shown). WT K-562 cells had relatively low ULBP1 expression, and mutation of ATF4
resulted in the complete disappearance of ULBP1 from the cell surface, as well as an 11-fold reduction
in ULBP1 mRNA (Figure 4A,B). In contrast, ATF4-deficiency in Jurkat cells resulted in a modest
reduction in ULBP1 mRNA and a barely detectable reduction in ULBP1 cell surface staining. By
comparison, HAP1 cells showed intermediate effects of ATF4-deficiency. The results suggest that
ATF4 drives basal ULBP1 expression in multiple tumor cell lines, perhaps reflecting constitutive
activation of underlying stress pathways.

ATF4 drives ULBP1 transcription in response to cell stress
ATF4 is induced in a variety of stress conditions that arise in unhealthy, infected, and transformed
cells; coupling these stress conditions to NKG2D ligand expression may enable destruction of
undesirable cells. Such stresses, including amino acid starvation, the unfolded protein response (UPR),
oxidative stress, and the presence of dsRNA, induce ATF4 through phosphorylation of the translation
initiation factor eIF2α (Rutkowski and Kaufman, 2003; Suragani et al., 2012). Phosphorylation of
eIF2α globally suppresses protein translation but selectively activates the translation of ATF4 (Harding
et al., 2000). The transcriptional targets of ATF4 include amino acid transporters and protein
chaperones, which in combination with the overall reduction in protein synthesis help mitigate the
cellular stress (Harding et al., 2003). However, ATF4 expression also drives the expression of the proapoptotic transcription factor CHOP (GADD153), suggesting that ATF4 not only drives adaptation to
stress but also promotes cell death if the stress cannot be overcome (Tabas and Ron, 2011;
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Figure 3. Double and triple-mutant cell lines show stepwise decreases in ULBP1 expression. (A) Flow cytometric analysis of ULBP1 expression on single,
double, and triple-mutant HAP1 cells. ATF4−/RBM4− double-mutant cells were generated by mutagenesis of ATF4 in RBM4− cells. Triple-mutant cells
were generated by mutagenesis of HSPA13 or SPCS2 in ATF4−/RBM4− double-mutant cells. Shaded gray histograms represent isotype control staining.
Data are representative of three independent experiments. (B) RT-qPCR analysis of canonically spliced ULBP1 mRNA expression levels in the cells
described in (A). Expression levels were normalized to ACTB, GAPDH, and HPRT1 and are shown as mean ±SE. The data were analyzed by 1-way ANOVA
with Bonferroni’s multiple comparisons test and substantive significant differences are shown. Data are representative of three independent experiments.
*p < 0.05, **p < 0.01, ***p < 0.001, n.s.: not significant.
DOI: 10.7554/eLife.08474.010

Han et al., 2013). Increased ATF4 expression has been detected in some tumors (Bi et al., 2005),
providing a possible mechanism for coupling malignant transformation to expression of ULBP1, and
consequently to tumor immunosurveillance.
To impart stress known to induce ATF4 expression, we treated cells with the drug histidinol (HisOH),
which competitively inhibits histidine–tRNA charging, thus mimicking amino acid starvation (Hansen
et al., 1972; Thiaville et al., 2008), or thapsigargin (Tg), which induces the UPR (Oslowski and Urano,
2011). Histidinol or thapsigargin treatment each significantly induced ULBP1 mRNA in WT K-562, HAP1,
and Jurkat cells, but induction was abrogated or severely blunted when cells lacked ATF4 (Figure 5A).
Induction of ULBP1 transcription by the proteasome inhibitor MG132 (Butler et al., 2009) was not
prevented in the ATF4-mutant cells (data not shown), indicating that certain cellular perturbations
transcriptionally activate ULBP1 independently of ATF4. RNA-Seq analysis of HAP1 cells confirmed
ATF4-dependent upregulation of ULBP1 mRNA in response to histidinol treatment (Figure 5—figure
supplement 1). RT-qPCR analysis of other NKG2D ligands expressed by HAP1 cells showed that
histidinol treatment caused an increase in ULBP2 mRNA that was partially ATF4-dependent, while MICA
expression was slightly decreased in an ATF4-independent manner (Figure 5—figure supplement 2).
ULBP3 and MICB transcripts were not affected by histidinol treatment or loss of ATF4 (Figure 5—figure
supplement 2). ULBP4, ULBP5, and ULBP6 mRNAs were absent or barely detectable by RNA-Seq
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Figure 4. ATF4 drives basal ULBP1 expression in multiple cell lines. (A) Flow cytometric analysis of ULBP1 expression
on WT versus ATF4 KO variants of K-562, HAP1, and Jurkat cells. Data are representative of three independent
experiments. (B) RT-qPCR analysis of canonically spliced ULBP1 mRNA expression levels in the cells described in (A).
Expression levels were normalized to ACTB, GAPDH, and HPRT1 and are shown as mean ±SE. Expression in
WT cells was set to ‘1.0’ for each cell type; the different cell types are not comparable in this experiment. The data
were analyzed by 2-way ANOVA with Bonferroni’s multiple comparisons test. Data are representative of three
independent experiments, though one of the three Jurkat analyses did not show a significant difference. *p < 0.05,
***p < 0.001.
DOI: 10.7554/eLife.08474.011

analysis of untreated HAP1 cells, and those genes showed no sign of induction by histidinol (data not
shown). These data suggest that the ATF4-mediated stress response induces expression of ULBP1, and
to a minor extent ULBP2, but not most other NKG2D ligands.
Stress-induced cell surface ULBP1 protein expression was also examined. Although histidinol and
thapsigargin induce transcription of ATF4-regulated genes, they also inhibit protein synthesis, both
directly (e.g., by limiting the availability of charged histidine tRNAs) and indirectly, by causing eIF2α
phosphorylation. These opposing effects make it difficult to predict whether stress induction will
result in increased amounts of any specific protein encoded by an ATF4-regulated gene.
Nevertheless, in K-562 cells, we observed a dramatic ATF4-dependent induction of cell surface
ULBP1 by histidinol (Figure 5B,D). In HAP1 and Jurkat cells, in contrast, addition of histidinol induced
ULBP1 cell surface expression slightly in WT cells, but caused decreased ULBP1 expression in ATF4mutant cells (Figure 5B,D), consistent with the aforementioned inhibition of protein synthesis
resulting from histidinol treatments. Indeed, histidinol treatments resulted in substantially decreased
cell surface expression of HLA proteins, which are not regulated by ATF4 (Figure 5C,E). As
summarized in Figure 5D, the overall effect of ATF4 induction by histidinol was to induce and/or

Gowen et al. eLife 2015;4:e08474. DOI: 10.7554/eLife.08474

9 of 26

Research article

Immunology

Figure 5. ATF4 drives increased expression of ULBP1 mRNA and surface protein in response to cell stress. (A) Cells
were treated for 24 hr with 2 mM histidinol (HisOH) to mimic amino acid starvation or 300 nM thapsigargin (Tg) to
induce the unfolded protein response. RNA was isolated from treated and control cells, and canonically spliced
ULBP1 mRNA levels were determined by RT-qPCR. Expression levels were normalized to ACTB, GAPDH, and HPRT1
and are shown as mean ±SE. Expression in untreated WT cells was set to ‘1.0’ for each cell type; the different cell
types are not comparable in this experiment. For reference, the Cq values for ULBP1 in untreated WT cells were 32.2
for K-562 cells, 27.9 for HAP1 cells, and 30.5 for Jurkat cells. The data were analyzed by 2-way ANOVA with
Bonferroni’s multiple comparisons test and are representative of three independent experiments, though in one of
the three analyses of ATF4 KO Jurkat cells, histidinol-treated cells trended higher than untreated cells but did not
reach significance. *p < 0.05, ***p < 0.001, n.s.: not significant. (B, C) Flow cytometric analysis of ULBP1 (B) and HLA
Class I expression (C) on cells treated with histidinol as in (A). (D, E) Quantification of surface staining shown in
(B) and (C). Data are plotted as the geometric mean fluorescence intensity of the specific stain minus the intensity of
the isotype control (ΔgMFI). Data are representative of three independent experiments.
DOI: 10.7554/eLife.08474.012
The following figure supplements are available for figure 5:
Figure supplement 1. Analysis of ULBP1 expression by RNA-Seq.
DOI: 10.7554/eLife.08474.013
Figure supplement 2. Analysis of other NKG2D ligands in response to cell stress.
DOI: 10.7554/eLife.08474.014
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maintain ULBP1 cell surface expression in the face of global protein synthesis inhibition associated
with this stress pathway.
To address whether ATF4 directly regulates ULBP1 transcription, we used ChIP-Seq analysis to
determine whether it binds to ULBP1 regulatory elements in histidinol-treated HAP1 cells. ChIP-Seq
with three independent ATF4 antibodies showed a strong peak of ATF4 binding associated with the
ULBP1 promoter, along with a smaller peak ∼27 kb downstream in the intergenic region, which could
function as an enhancer. No other notable ATF4 binding was observed in the 266 kb interval shown,
which includes genes encoding five other functional NKG2D ligands (ULBP2-6; RAET1K is a
pseudogene), at least two of which are expressed in HAP1 cells (ULBP2 and ULBP3) (Figure 6A, data
not shown). The MICA and MICB genes were also devoid of ATF4 binding (data not shown). HOMER
Motif Analysis software identified ATF4-binding motifs in both peaks (Figure 6B,C) (Heinz et al.,
2010). Additional ATF4-binding motifs were present in the segment shown but were not bound by
ATF4. ATF4 binding at the ULBP1 promoter was confirmed by conventional ChIP-qPCR, which also
demonstrated that ATF4 binds to the ULBP1 locus in HAP1 cells under steady-state conditions (no
histidinol), and that ATF4 binding is sharply enhanced after histidinol treatment (Figure 6D,E).
A similar pattern of ATF4 binding was observed at the ASNS promoter, a known target of ATF4, but
not at a negative control site in the ASNS gene body (Figure 6D,E, Figure 6—figure supplement 1)
(Chen et al., 2004).
We used luciferase reporter assays to confirm direct activation of the ULBP1 promoter by ATF4.
We inserted previously described fragments of the ULBP1 promoter (López-Soto et al., 2006)
and 5ʹ UTR upstream of a luciferase reporter and tested promoter responsiveness to ATF4
overexpression in ATF4-deficient HAP1 cells (Figure 6—figure supplement 2). ATF4 overexpression increased ULBP1 promoter activity, and the fold-induction was similar for the longer and
shorter promoter fragments tested. To identify the relevant ATF4-binding site(s), we employed the
shorter promoter fragment and mutated either the ATF4 motif we had identified, or each of two
Cyclic AMP Response Element (CRE) sites, which were previously shown to drive ULBP1 promoter
activity and are similar to the ATF4 consensus sequence. Mutation of the ATF4 motif 138–147 bp
upstream of the transcription start site completely ablated promoter activation by ATF4 (see mutant
1, m1), while mutation of the CRE sites did not reduce induction by ATF4. We conclude that ATF4
directly transactivates the ULBP1 promoter, and that a single ATF4-binding site drives the bulk of
this response.

RBM4 suppresses alternative splicing of ULBP1 mRNA
RBM4 is an RNA-binding protein that has been implicated in several steps of gene regulation but has
been most studied for its regulation of RNA splicing (Markus and Morris, 2009). We compared WT
and RBM4 KO HAP1 cells by RNA-Seq to determine a potential role of RBM4 in splicing of ULBP1
transcripts. As a result, we discovered a novel isoform of ULBP1 that to our knowledge has not been
previously reported (Figure 7A). The sequence of the novel isoform has been deposited in GenBank
(Accession number KT591165). Analysis of sequence reads that aligned to splice junctions revealed
that most transcripts in WT cells exhibited the expected splicing pattern to encode the normal ULBP1
protein (Figure 7A,B). In RBM4 KO cells, in contrast, approximately 60% of transcripts had undergone
an alternative splicing event of the first and second exons in which the 5ʹ splice site at the 3ʹ border of
the first exon was ignored in favor of a 5ʹ splice site located 1.3 kb downstream within the first intron
(Figure 7A). Splicing of the downstream exons of ULBP1 appeared normal in RBM4 KO cells. The
alternatively spliced transcript in RBM4 KO cells encodes a premature stop codon shortly after the
predicted ER signal peptide and is thus unlikely to encode a functional protein fragment (Figure 7C).
We did not observe differential splicing of the other NKG2D ligands expressed by HAP1 cells (MICA,
MICB, ULBP2, and ULBP3, Figure 7—figure supplement 1).
The alternative splicing of ULBP1 transcripts in RBM4 KO cells was confirmed by RT-qPCR analysis
(Figure 7C–E, Figure 7—figure supplement 2). Canonically spliced ULBP1 transcripts were less
abundant in RBM4 KO cells, while the alternatively spliced transcripts were more abundant; the overall
abundance of ULBP1 transcripts was unchanged as a result of RBM4-deficiency. The reduction in
canonically spliced transcripts was commensurate with the reduction in cell surface ULBP1 protein,
suggesting that RBM4 impacts cell surface expression of ULBP1 primarily by facilitating the correct
splicing of the first two exons of ULBP1 transcripts.
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Figure 6. ATF4 is bound to the ULBP1 promoter and a potential downstream regulatory element. (A) ATF4 ChIPSeq: HAP1 cells were treated with 2 mM histidinol (HisOH) for 24 hr, followed by formaldehyde cross-linking. ATF4bound chromatin was immunoprecipitated using three independent anti-ATF4 antibodies, and the isolated DNA
was sequenced and aligned to the human genome (hg19). Locations of consensus ATF4-binding motifs are
indicated. RAET1K is a pseudogene (ψ). (B, C) HOMER Motif Analysis software identified the ATF4 binding motif (B)
and its reverse-complement (C). (D, E) Conventional ChIP-qPCR of ATF4 using the antibody sc-200 (D) or D4B8 (E).
Samples were treated as in (A), followed by qPCR. ChIP signal was normalized to the amount of Input DNA for each
sample. Data are plotted as mean ±SE and were analyzed by 2-way ANOVA with Bonferroni’s multiple comparisons
test. Representative data are shown. The ChIP-qPCR experiment was performed twice using both untreated and
HisOH-treated cells, and a third time using only HisOH-treated cells. *p < 0.05, ***p < 0.001, n.s.: not significant.
Raw sequencing data corresponding to ATF4 ChIP-Seq have been deposited to GEO. Accession: GSE69304.
DOI: 10.7554/eLife.08474.015
The following figure supplements are available for figure 6:
Figure supplement 1. ATF4 ChIP-Seq signal at the ASNS promoter, a known ATF4-binding site.
DOI: 10.7554/eLife.08474.016
Figure supplement 2. ATF4 directly activates the ULBP1 promoter.
DOI: 10.7554/eLife.08474.017

Discussion
The mutant screen identified several regulators of ULBP1 in HAP1 cells. Loss-of-function mutations in
each of the corresponding genes resulted in relatively modest reductions in cell surface ULBP1 when
examined separately. The capacity of the screen to detect mutations that each have relatively small
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Figure 7. RBM4 suppresses the alternative splicing of ULBP1 mRNA. (A) ‘Sashimi plots’ of RNA-Seq reads aligning
to ULBP1 mRNA from WT and RBM4 KO HAP1 cells. Peak height represents the number of reads aligning to a given
segment (RPKM). Arcs connect splice junctions identified by reads spanning the splice junction; the number of reads
aligning to each splice junction is indicated. (B) Quantification of splice junction-spanning reads mapping to
canonical or alternatively spliced ULBP1 mRNA. Reads spanning the canonical or alternative splice junction are
expressed as a percent of the total junction-spanning reads (canonical + alternative). n.d.: not detected. (C) Diagram
of the canonical and alternatively spliced isoforms of the ULBP1 mRNA. The alternative isoform contains a premature
stop codon and is unlikely to produce a functional protein product. The PCR amplicons used in (D–F) are indicated.
(D–F) RT-qPCR analysis of ULBP1 transcript levels in WT and RBM4 KO HAP1 cells. Cells were transduced with a
doxycycline-inducible RBM4 vector or control vector and treated with 100 ng/ml Dox for 24 hr. The data were
analyzed by 1-way ANOVA with Bonferroni’s multiple comparisons test and are representative of three independent
experiments. **p < 0.01, ***p < 0.001, n.s.: not significant.
DOI: 10.7554/eLife.08474.018
The following figure supplements are available for figure 7:
Figure supplement 1. Splicing of other NKG2D ligands is unchanged in RBM4 KO HAP1 cells.
DOI: 10.7554/eLife.08474.019
Figure supplement 2. Additional analysis of ULBP1 transcript in WT and RBM4 KO HAP1 cells.
DOI: 10.7554/eLife.08474.020

effects demonstrates its remarkable power to identify pathways that function in a partially redundant
fashion. Overall, the data suggest that most of the pathways studied control different steps in the
biogenesis of ULBP1, with ATF4 controlling transcription, RBM4 regulating RNA splicing, and
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HSPA13, SCPS1, and SPCS2 regulating co-translational or post-translational steps such as protein
processing. The power of the CRISPR/Cas9 method to rapidly generate double- and triple-mutant cell
lines led to the finding that disabling multiple regulators resulted in much more striking reductions in
ULBP1 expression than disabling them individually. Thus, each regulator contributes incrementally
to ULBP1 expression. This finding lends support to the hypothesis that stress pathways might
cumulatively control the amount of a given NKG2D ligand displayed on the cell to define a
quantitative ‘threat level’ confronting a cell (Raulet et al., 2013). Previously published evidence
demonstrated that greater NK-dependent tumor elimination occurs with increasing amounts of cell
surface NKG2D ligand (Diefenbach et al., 2001), consistent with the ‘threat-level’ hypothesis.
When characterizing the phenotypes of our mutant HAP1 cell lines, we were surprised to find that
in each case, ULBP1 was the only NKG2D ligand with substantially altered expression, the one
exception being an increase in MICB expression observed on HSPA13 KO cells. These data provide
strong support for the proposal that different ligands are specialized with respect to their regulatory
mechanisms, providing the capacity to respond to specific classes of threats (Raulet et al., 2013). In
contrast, certain other regulatory pathways, such as the DNA damage response, regulate several
NKG2D ligands similarly (Gasser et al., 2005; Soriani et al., 2009; Raulet et al., 2013). The system as
a whole, therefore, encompasses both generic and specific regulators.

ATF4 and transcription of ULBP1
A key finding was that ATF4, a mediator of several stress responses, transcriptionally activates ULBP1.
The data show that ATF4 binds to two locations at the ULBP1 locus, including the promoter region,
that an ATF4 site in the ULBP1 promoter is essential for ATF4-induced transcription, and that ATF4
drives ULBP1 transcription in wild-type cells. No additional ATF4 binding or transcriptional induction
was detected for most other NKG2D ligand genes, although ULBP2 was modestly upregulated by
histidinol treatment in a manner partially dependent on ATF4. Since ATF4 was not bound to the
ULBP2 promoter, we speculate that ULBP2 transcription is regulated by a transcription factor that is
induced by ATF4, or that ATF4 binding to the sites in the ULBP1 gene modestly activates the
neighboring ULBP2 gene.
Disruption of ATF4 resulted in reduced ULBP1 expression under steady-state conditions in all three
of the cell lines tested. These data suggest that ATF4 activity caused by constitutive stress in tumor
cell lines contributes to ULBP1 expression. This finding has physiological relevance, as overexpression
of UPR components has been found in primary tumors and cell lines derived from breast cancers
(Fernandez et al., 2000; Fujimoto et al., 2003), hepatocellular carcinomas (Shuda et al., 2003), and
multiple myeloma (Reimold et al., 1996; Munshi et al., 2004).
The three cell lines we examined illustrate the different ways that ATF4 can support steady-state
ULBP1 expression in different contexts. In some cases, expression of ULBP1 may be critically
dependent on ATF4. This is the case in unstimulated K-562 cells in which basal ULBP1 expression was
detected (though weakly) in WT cells but was absent from the surface of ATF4 KO cells. In other cases,
exemplified by HAP1 and Jurkat cells, numerous factors contribute to ULBP1 expression, with ATF4
being only one of them. Those cells had higher basal ULBP1 expression than K-562 cells and showed a
modest decrease in ULBP1 expression when ATF4 was mutated.
The impact of ATF4 on ULBP1 transcription was most notable when additional stressors were
applied that induce ATF4 expression. Outcomes at the level of protein expression are difficult to
predict a priori, because these stressors induce transcription of ATF4 target genes, but also cause
global suppression of translation as a result of eIF2α phosphorylation. We observed a range of
outcomes in different cell lines. Amino acid starvation of K-562 cells, imparted by histidinol treatment,
caused a substantial increase in ULBP1 mRNA and surface protein, and the response was ablated in
ATF4 KO cells. In this case, the increase in ULBP1 transcription overwhelmed the global decrease in
translation. In contrast, in HAP1 and Jurkat cells, amino acid starvation of WT cells caused a fivefold to
sevenfold increase in ULBP1 mRNA, but a much smaller increase in ULBP1 protein at the cell surface.
Nevertheless, the impact of ATF4 was made apparent by the observation that ULBP1 protein levels
decreased on the surface of similarly stressed ATF4 KO cells. In these cell lines, therefore, the induction
of ULBP1 transcription by ATF4 serves to maintain (and slightly increase) expression of ULBP1 protein
in the face of cellular stress. Maintaining ULBP1 expression that is induced by distinct regulatory
pathways is important in cells where translational inhibition is likely to occur, such as in hypoxic tumors.
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Our finding that ULBP1 expression is regulated by ATF4 fits the existing paradigm for ATF4 target
genes. ATF4 is induced by amino acid starvation, oxidative stress, hypoxia, and the UPR. ATF4 target
genes include amino acid transporters, anti-oxidant response genes, angiogenic factors, and protein
chaperones, and thus, ATF4 initially promotes cell survival against these insults (Jain, 2005; Roybal
et al., 2005; Han et al., 2013). Previous studies have shown that ATF4 expression is frequently
induced in primary tumors and tumor cell lines (Fernandez et al., 2000; Shuda et al., 2003; Ma and
Hendershot, 2004). Inadequate vascularization can cause tumors to become hypoxic and nutrientstarved, two conditions known to induce ATF4. Indeed, ATF4 expression is highest in hypoxic regions
of tumors (Ameri et al., 2004; Bi et al., 2005). However, the pro-apoptotic targets of ATF4, such
as CHOP, provide an important safety mechanism for the host (Tabas and Ron, 2011). Without a
pro-apoptotic component, the transcriptional targets of ATF4 would be ripe for exploitation by
expanding tumors, which are often poorly vascularized, and consequently both hypoxic and starved.
Upregulation of ULBP1 by ATF4 provides an additional layer of host defense, marking potentially
dangerous cells for elimination by the immune system. Although not explored in this study, induction
of ULBP1 by ATF4 may also play a role in antiviral immunity. As mentioned above, ATF4 expression is
induced by phosphorylation of eIF2α. Viral infection can activate PERK and PKR, which phosphorylate
eIF2α and therefore induce ATF4 expression (Mohr and Sonenberg, 2012; Jheng et al., 2014).

RBM4 and splicing of ULBP1 transcripts
We identified RBM4 as a second factor responsible for steady-state ULBP1 expression in HAP1 cells.
RBM4-deficient cells exhibited a twofold to threefold reduction in cell surface ULBP1 and the
corresponding canonical ULBP1 mRNA isoform. Interestingly, RBM4 suppresses a novel alternative
splicing event in the ULBP1 transcript. In the absence of RBM4, total ULBP1 mRNA levels were
unchanged, but the alternatively spliced isoform was upregulated while the canonically spliced
isoform was downregulated. The alternative ULBP1 transcript contains a premature stop codon early
in the protein-coding sequence and is unlikely to produce a functional protein. Transcripts containing
premature stop codons can be targets for nonsense-mediated decay (NMD) (Maquat, 2004), but we
could nonetheless detect the alternative ULBP1 transcript by RNA-Seq. The degree to which the
alternative ULBP1 transcript is degraded by NMD is presently unclear. RBM4 has also been implicated
in other forms of gene regulation, including translation and microRNA-mediated gene silencing
(Lin and Tarn, 2009; Uniacke et al., 2012). In HAP1 cells, however, the change in cell surface ULBP1
in RBM4 KO cells was commensurate with the change in canonically spliced transcripts, suggesting
that these other mechanisms do not play an appreciable role. It remains possible that RBM4 influences
ULBP1 translation or gene expression in other cells or contexts.
It was recently reported that RBM4 regulates the alternative splicing of numerous cancer-related
genes. Most interesting, in light of our findings, was the finding based on RNA-Seq analysis that RBM4
expression promoted a tumor-suppressive splicing profile (Wang et al., 2014a). This action occurred in
part through the alternative splicing of the BCL2L1 gene (Bcl-x), wherein RBM4 promoted splicing that
generated the pro-apoptotic isoform Bcl-xS, at the expense of the anti-apoptotic isoform Bcl-xL. Our
data suggest that RBM4 further promotes tumor suppression by favoring the canonical splicing of ULBP1
mRNA, marking cells for elimination by the immune system. Decreased RBM4 expression has been
observed in various cancers compared to paired healthy tissues, including lung, breast, and pancreatic
cancers. Furthermore, lower RBM4 expression correlated with decreased patient survival (Wang et al.,
2014a). We speculate that tumor cells are under selective pressure to downregulate RBM4 expression,
as this would allow tumors to evade tumor-suppressive events such as expression of Bcl-xS and ULBP1.
An interesting question is whether the splicing functions of RBM4 are subject to stress-regulation.
Intriguingly, the subcellular localization of RBM4 is reportedly regulated by oxidative stress or activation of
the MKK3/6-p38 MAPK pathway. In that instance, however, stress favored the cytoplasmic localization of
RBM4 (Lin et al., 2007), where it reportedly enhanced translation of a subset of mRNAs (Lin et al., 2007; Lin
and Tarn, 2009; Uniacke et al., 2012). Additional studies will be necessary to establish whether regulated
re-localization of RBM4, or other types of regulation, impact alternative splicing of ULBP1 or other transcripts.

HSPA13
HSPA13 (also known as STCH) belongs to the Hsp70 family of chaperone proteins (Otterson et al.,
1994). HSPA13 is associated with microsomes and displays ATPase activity, but little is known about its
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function, including whether HSPA13 participates in cellular stress responses. One report showed that
HSPA13 binds to the ion transporters NBCe1 and NHE1, which help maintain intracellular pH
homeostasis (Bae et al., 2013). HSPA13 overexpression increased NBCe1 and NHE1 protein levels and
functional activity. It will be interesting to pursue the mechanisms by which HSPA13 supports
expression of ULBP1, which could be through direct or indirect effects.

SPCS1 and SPCS2
SPCS1 and SPCS2 are non-catalytic subunits of the signal peptidase complex, but surprisingly little is
known about their function (Mullins et al., 1996). We were surprised that HAP1 cells lacking SPCS1 or
SPCS2 did not have a more general defect in cell surface protein expression; out of seven cell surface
proteins tested, only ULBP1 expression was decreased. However, it should be noted that seven proteins
represent a small fraction of the proteome, and we expect that a proteome-wide investigation would
reveal many additional affected proteins. In yeast, SPCS1 and SPCS2 are required for maximal signal
peptidase activity under certain growth conditions (Fang et al., 1996; Mullins et al., 1996), and in
mammalian cells, SPCS1 supports expression of the HCV protein NS2 (Suzuki et al., 2013). It will be of
future interest to define the properties that determine if a given secreted or membrane protein depends
on SPCS1 and SPCS2 for maximal expression.

Final remarks
The drivers of ULBP1 expression we have identified are likely to cooperate with previously described
stress pathways that regulate ULBP1. Other transcription factors known to bind the ULBP1 gene and
drive gene expression include Sp1, Sp3, and the tumor suppressor protein p53 (López-Soto et al.,
2006; Textor et al., 2011). It is possible that one or more of these factors contribute to ULBP1
transcription in HAP1 and Jurkat cells, considering that residual ULBP1 expression was observed even
after ATF4 was disrupted. Additional stress pathways including heat shock, E2F transcription factors,
and the DNA damage response drive expression of other NKG2D ligands, and the combined
expression level of all the NKG2D ligands on a given cell will contribute to its ability to activate NK
cells (Gasser et al., 2005; Venkataraman et al., 2007; Jung et al., 2012). HAP1 cells may be
representative of a very high ‘threat level’, as they had activated numerous ULBP1 drivers, and
independent drivers for several other NKG2D ligands. Moreover, these cells possessed potent
NK-activating properties distinct from NKG2D ligands, as shown by studies with NKG2D-deficient NK
cells (data not shown). Probably as a consequence, loss of ULBP1 drivers, and even ULBP1 itself, had
little detectable effect on the capacity of HAP1 cells to stimulate a response (data not shown).
The layers of ULBP1 regulation we have described could allow NKG2D ligand expression to be
fine-tuned to reflect the ‘threat level’ of the cell. ATF4 could upregulate ULBP1 transcription, but
other factors may amplify the extent of ULBP1 transcription. Maximal cell surface expression would
require RBM4 to direct splicing of the functional mRNA isoform, followed by maximal translation and
trafficking of the protein to the cell surface. Ubiquitous RBM4 expression is ‘safe’ for normal, healthy
cells, since functional ULBP1 cannot be spliced unless the gene is transcribed in the first place.
The results of our screen highlight diverse mechanisms for the control of NKG2D ligand expression.
To the best of our knowledge, none of the hits we investigated are related to previously known drivers
of ULBP1 or other NKG2D ligands, and the effects found were generally specific to ULBP1. Screens for
drivers of other NKG2D ligands will be the subject of future work, and the advent of CRISPR/Cas9based screens will enable screens to be carried out in many different cell lines (Gilbert et al., 2014;
Shalem et al., 2014; Wang et al., 2014b).

Materials and methods
Cells, antibodies, and reagents
Cell cultures were performed at 37˚C in humidified atmosphere containing 5% CO2. HAP1 cells were
cultured in complete IMDM, consisting of IMDM (Life Technologies, Carlsbad, CA), 10% fetal calf serum
(FCS, Omega Scientific, Tarzana, CA), 100 U/ml penicillin (Life Technologies), 100 μg/ml streptomycin
(Life Technologies), and GlutaMAX-I (Life Technologies). K-562 and Jurkat cells were cultured in complete
RPMI, consisting of RPMI (Life Technologies), 10% FCS, 1 mM sodium pyruvate (Life Technologies), MEM
non-essential amino acids (Life Technologies), 100 U/ml penicillin, 100 μg/ml streptomycin, 0.2 mg/ml
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glutamine (Sigma–Aldrich, St. Louis, MO), 10 μg/ml gentamycin sulfate (Lonza, Basel, Switzerland), 20
mM HEPES (Thermo Fisher Scientific, Waltham, MA), and 50 μM 2-mercaptoethanol (EMD Millipore,
Billerica, MA).
Antibodies against ULBP1 (Clone 170818), ULBP2/5/6 (Clone 165903), ULBP3 (Clone 166510),
MICA (Clone 159227), and MICB (Clone 236511) were purchased from R&D Systems. Antibodies
against HLA-A,B,C (Clone W6/32), CD55 (Clone JS11), CD59 (Clone p282 H19), CD112 (Clone TX31),
and CD155 (Clone TX24), and mouse Thy1.1 (Clone OX-7) were purchased from BioLegend (San Diego,
CA). In some experiments, the antibodies against HLA-A,B,C (Clone W6/32) and CD59 (Clone OV9A2)
were purchased from eBioscience (San Diego, CA). Antibodies against ATF4 used for chromatin
immunoprecipitation (ChIP) were sc-200 (polyclonal) (Santa Cruz Biotechnology, Santa Cruz, CA), D4B8
(monoclonal) (Cell Signaling Technologies, Danvers, MA), and ABE387 (polyclonal) (EMD Millipore).
Histidinol, thapsigargin, and RNase A were purchased from Sigma–Aldrich. Proteinase K was purchased
from Roche (Basel, Switzerland).

Retroviral gene-trap mutagenesis and screen
Mutagenesis of HAP1 cells was performed as previously described (Carette et al., 2011). Selection of
ULBP1low cells was performed using sequential rounds of selection. First, 108 mutagenized HAP1 cells
were labeled with ULBP1 antibody, and ULBP1high cells were depleted by running the cells over two
sequential MACS LD columns (Miltenyi Biotec, San Diego, CA). Depletion of ULBP1high cells on this day
was less efficient than we had achieved in previous experiments, so we chose to re-plate the selected
cells, expand the cells for 2 days, and repeated the magnetic depletion of ULBP1high cells. We speculate
that a single round of magnetic depletion may have been sufficient if adequate depletion of ULBP1high
cells had been achieved. Magnetically selected cells were re-plated and expanded for 5 days. Expanded
cells were labeled with ULBP1 and CD55 antibodies, and ULBP1lowCD55+ cells were sorted by FACS, replated, and expanded. Genomic DNA was isolated from 4 × 107 cells. Mapping of gene-trap insertion
sites and statistical analysis were performed as previously described (Carette et al., 2011).

Flow cytometry
Cells were stained with the specified antibodies in 50 μl of PBS supplemented with 2.5% FCS or 1%
BSA (FACS buffer). FACS buffer included 0.05% sodium azide for analytical flow cytometry, but not
cell sorting. Dead cells were excluded from analysis by staining with DAPI (BioLegend). Multicolor flow
cytometry was performed on an LSR Fortessa cytometer (BD Biosciences, San Jose, CA), and data
were analyzed with FlowJo software (Tree Star, Inc., Ashland, Oregon).

CRISPR/Cas9 gene targeting
Mutant HAP1 cells were generated by transiently co-transfecting cells with a Cas9 expression vector
(pMJ918, a gift from Jennifer Doudna), an sgRNA expression vector (Addgene plasmid #41824, a gift
from George Church), and a GFP expression vector using Lipofectamine 2000. Transfected cells were
sorted based on GFP expression 24–72 hr post-transfection. To enrich cells with a mutant phenotype,
cells were stained for ULBP1 expression 5–7 days post-transfection, and single ULBP1low cells were
sorted into 96-well plates. Mutant cell clones were identified by sequencing PCR products
surrounding the Cas9:sgRNA target site. sgRNA sequences are listed in Table 2. PCR primers used
to detect mutations are listed in Table 3.
ATF4 KO K-562, Jurkat, and HAP1 cells were generated using two sgRNAs flanking ATF4 (ATF4 sgRNA
2 and ATF4 sgRNA 3) in order to delete the entire ATF4 gene. Cells were transiently co-transfected with
GFP and the Cas9/sgRNA expression plasmid px330 (Addgene plasmid #42230, a gift from Feng Zhang).
Transfected cells were sorted based on GFP expression 24–72 hr post-transfection. 5–7 days posttransfection, single cells were sorted into 96-well plates without any additional selection.

Lentiviral transduction of doxycycline-inducible constructs
For doxycycline-inducible gene expression, constructs encoding ATF4, RBM4, HSPA13, SPCS1, and
SPCS2 were cloned into the lentiviral vector pFG12-TRE-UbC-rtTA-Thy1.1 (hereafter pFG12). The
ATF4 construct was a gift from Yihong Ye (Addgene plasmid #26114). The RBM4 construct was a gift
from Lan Ko, Georgia Health Sciences University. The HSPA13 construct was a gift from Kyungpyo
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Table 2. sgRNA sequences
sgRNA Sequence + PAM

Name

Used in

ULBP1 sgRNA

GGGTCCCGGGCAGGATGGGTCGG

HAP1

ATF4 sgRNA 1

GGCGGGCTCCTCCGAATGGCTGG

HAP1

ATF4 sgRNA 2

GCTCGTCACAGCTACGCCCTGGG

HAP1, K-562, Jurkat

ATF4 sgRNA 3

GTGGCCAACTATACGGCTCCAGGG

HAP1, K-562, Jurkat

RBM4 sgRNA

GAGTCCCACCTGCACCAATAAGG

HAP1

RBM4/RBM4b sgRNA

GCCCCGGGAGGCTACAGAGCAGG

HAP1

HSPA13 sgRNA

GTGCCAAATAGCCGGCCAACAGG

HAP1

SPCS1 sgRNA

GCATCTGTTCAGCTAGCTTCTGG

HAP1

SPCS2 sgRNA

GAGTGGCCGTAGCGGCTTGTTGG

HAP1

PAM, protospacer adjacent motif.
For each sgRNA, the protospacer adjacent motif (PAM) is indicated in bold blue text. Red text indicates that the 5ʹ G
is not present in the genomic target sequence and was added to the sgRNA to allow transcription from the U6
promoter.
DOI: 10.7554/eLife.08474.021

Park, Seoul National University. The SPCS1 construct was a gift from Tetsuro Suzuki, Hamamatsu
University School of Medicine. SPCS2 was cloned from HAP1 cDNA.
Lentiviral supernatants were generated by co-transfecting 293T cells with pFG12 vector, the VSV-G
plasmid pMD2.G, and the packaging plasmid psPAX2 using Lipofectamine 2000 (Life Technologies).
Supernatants were harvested 48 hr post-transfection, filtered with a 0.45-μM PES syringe filter, and
added to target cell cultures with 4 μg/ml polybrene. Transduced cells were sorted based on Thy1.1
expression. To induce gene expression, cells were cultured in complete medium with 100 or 1000 ng/mL
doxycycline (Sigma–Aldrich), as noted in figure legends.

Quantitative real-time PCR
Total RNA was isolated from cells using the RNeasy Mini Kit and on-column DNase digestion using the
RNase-free DNase Set (Qiagen, Hilden, Germany). Reverse transcription was performed with iScript

Table 3. PCR primers used to detect mutations
Target
ULBP1 sgRNA target locus

ATF4 sgRNA 1 target locus

Deletion of ATF4 with sgRNAs 2 and 3

RBM4 sgRNA target locus

HSPA13 sgRNA target locus

SPCS1 sgRNA target locus

SPCS2 sgRNA target locus

Primer direction

Primer sequence

Amplicon size (bp)
401

Forward

ATAAACAGCCGTGGTGTGAG

Reverse

TGTCTGGGGAGATCACGATG

Forward

CATTCCTCGATTCCAGCAAAGC

Reverse

TGAGTGATGGGGCCAAGTGAG

Forward

CGTCCTCGGCCTTCACAATA

Reverse

TCTTCAGGATGAGGCTTCTGC

Forward

TGCACATAGAAGACAAGACGGC

Reverse

CCTTGTGTTCAGCCCTCTACCC

Forward

TGCTGTCTGAGAGGAGTGCT

Reverse

CCTCCAACTCTTCTGCGGTA

Forward

ATTTAATATCTTGCCCAGGCCC

Reverse

ACCCACAAATTTCTTACCAAACAT

Forward

AACCTCAAGTCCCAGCAAGC

Reverse

CGGGTCCAGGTTTGAAGTGT

345

442

332

476

394

466

DOI: 10.7554/eLife.08474.022
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Reverse Transcription Supermix (Bio-Rad, Hercules, CA). Quantitative real-time PCR was performed on
a CFX96 thermocycler using SsoFast EvaGreen Supermix (Bio-Rad) with the following cycling program:
Initial denaturation at 98˚C, 2ʹ, followed by 40 cycles of 98˚C, 2ʹʹ, 55˚C, 5ʹʹ. Data were analyzed with BioRad CFX Manager Software version 3.1. Gene expression was normalized to the reference genes
ACTB, GAPDH, and HPRT1, normalizing the gene of interest to the geometric mean of the three
reference genes (Vandesompele et al., 2002). qPCR primer sequences are listed in Table 4.

ChIP and ChIP-Seq
Cells were re-plated in fresh media 12–24 hr prior to treatment. Media was then replaced with fresh
media or fresh media containing 2 mM histidinol, and cells were incubated for 24 hr. Chromatin

Table 4. Primers used for qPCR
Target

Primer direction

Primer sequence (5ʹ-3ʹ)

Amplicon size (bp)

ACTB

Forward

TTGGCAATGAGCGGTTCC

92

Reverse

GTTGAAGGTAGTTTCGTGGATG

Forward

CAACAGCGACACCCACTCCT

Reverse

CACCCTGTTGCTGTAGCCAAA

Forward

AGGATTTGGAAAGGGTGTTTATTC

Reverse

CAGAGGGCTACAATGTGATGG

Forward

GCCAGGATGTCTTGTGAGCATGAA

GAPDH

HPRT1

Total ULBP1 (exon 3-exon 3)

Reverse

TTCTTGGCTCCAGGATGAAGTGCT

ULBP1 canonical isoform
(exon 1-exon 2)

Forward

ATCAGCGCCTCCTGTCCAC

Reverse

AAAGACAGTGTGTGTCGACCCAT

ULBP1 alternative isoform
(extended exon 1-exon 2)

Forward

GGAATTGCAGGAGGGTGGAG

Reverse

CAAAGGCTTTGGCCTTGTGGTTAA

ULBP1 spliced transcript
(exon 2-exon 3)

Forward

TAAGTCCAGACCTGAACCACA

Reverse

CCATTGAAGAGGAACTGCCAAG

ULBP1 alternative
isoform and primary
transcript
(exon 1-extended exon 1)

Forward

CCGGGCAGGATGGGTCG

Reverse

TGTCTGGGGAGATCACGATG

ULBP1 unspliced
transcript
(Intron 1-exon 2)

Forward

CCCTCAGAGGCCTTCACTTG

Reverse

AAGGCCTTTCATCCACCAGG

ULBP2

Forward

GCCGCTACCAAGATCCTTCT

Reverse

TCATCCACCTGGCCTTGAAC

Forward

CTCGCGATTCTTCCGTACCT

Reverse

TCTGGACCTCACACCACTGT

Forward

ATGTCCTGCCTGATGGGAATGGAA

Reverse

CAGCAGCAACAGCAGAAACATGGA

Forward

TGGATCTGTGCAGTCAGGGTTTCT

ULBP3

MICA

MICB

Reverse

TGAGGTCTTGCCCATTCTCTGTCA

ULBP1 promoter ChIP

Forward

GCTGTCAGATGACGAGCCC

Reverse

ATACACTGGGCGGGATCCTA

ASNS promoter ChIP

Forward

TGGTTGGTCCTCGCAGGCAT

Reverse

CGCTTATACCGACCTGGCTCCT

Forward

GCAGCTGAAAGAAGCCCAAGT

Reverse

TGTCTTCCATGCCAATTGCA

ASNS exon 7 ChIP

115

109

134

136

183

477

263

195

161

127

189

176

80

66

62

DOI: 10.7554/eLife.08474.023

Gowen et al. eLife 2015;4:e08474. DOI: 10.7554/eLife.08474

19 of 26

Research article

Immunology

complexes were cross-linked by replacing the culture media with fresh complete media containing 1%
formaldehyde, and cells were incubated at room temperature for 10 min. Cross-linking was quenched
by adding glycine to a final concentration of 0.125 M. Cells were washed two times with ice-cold PBS,
and cell pellets were flash-frozen in a slurry of dry ice and ethanol.
Cells were resuspended in ChIP Lysis Buffer #1 (see buffer compositions below), incubated for 10ʹ at
4˚C with rotation, and centrifuged for 8ʹ at 800×g at 4˚C. Pellets were resuspended in ChIP Lysis Buffer
#2, incubated for 10ʹ at 4˚C with rotation, and centrifuged for 8ʹ at 800×g at 4˚C. Pellets were
resuspended in 3 volumes (∼200 μl) of ChIP Lysis Buffer #3. Chromatin was sheared to an average
fragment size of 200 bp using a Covaris S2 Ultrasonicator (Covaris, Woburn, MA). Sheared chromatin
was diluted in additional ChIP Lysis Buffer #3, followed by addition of Triton X-100 (final concentration
1%) and NaCl (final concentration 150 mM) and divided into 1 ml aliquots for immunoprecipitation.
Antibody was added to chromatin samples, followed by overnight incubation at 4˚C, with rotation.
Antibody-chromatin complexes were captured with Protein G Dynabeads (Life Technologies) at 4˚C for
2 hr, with rotation. Beads were washed 2× with low-salt wash buffer, 1× with high-salt wash buffer, 1×
with LiCl wash buffer, and 2× with TE. Beads were resuspended in ChIP elution buffer, and chromatin
was eluted by incubating samples at 65˚C for 15ʹ. Supernatant containing eluted chromatin was
removed from the beads and the cross links were reversed by incubating samples overnight at 65˚C.
RNase A was added to samples to a final concentration of 0.2 mg/ml, followed by incubation at
37˚C for 1 hr. Proteinase K was then added to a final concentration of 0.4 mg/ml, followed by
incubation at 56˚C for 1 hr. DNA was then isolated using the Qiagen MinElute Kit, followed by qPCR
as described above or Illumina Library prep.
ChIP-Seq libraries were prepared using the NEBNext Ultra DNA Library Prep Kit for Illumina (New
England BioLabs, Ipswich, MA), including optional size selection of adapter-ligated DNA and 13 cycles
of PCR amplification. Final libraries were analyzed with a Qubit fluorometer (Life Technologies) and
Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA) to assess quantity and quality. Libraries
were clustered at a density of 6.5 pM with a cluster station and sequenced on a GAIIx Genome
Analyzer (Illumina, San Francisco, CA).
ChIP-Seq reads were aligned to the human genome (hg19) using Bowtie2 version 2.1.0 using all
default settings (Langmead and Salzberg, 2012). Reads that could not be uniquely mapped were
discarded. Read densities were normalized to the total number of aligned reads in a sample using
Bedtools version 2.17.0 (Quinlan and Hall, 2010). ATF4-binding peaks were identified with HOMER
version 4.7 (Heinz et al., 2010) using the program findPeaks with the following options:
-style factor -i <input_tagdir>
where <input_tagdir> is a directory of ChIP-Seq reads from the input DNA fraction. ATF4 binding
motifs were identified with HOMER version 4.7 using the program findMotifsGenome.pl with the
following options:
-size 50 -mask
Data were visualized with the Integrative Genomics Viewer (IGV) version 2.3.47 (Robinson et al., 2011).

ChIP buffer compositions and antibody concentrations
ChIP Lysis Buffer #1: 50 mM HEPES pH 7.5, 140 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% NP-40,
0.25% Triton X-100, Protease Inhibitors*
ChIP Lysis Buffer #2: 10 mM Tris pH 8.0, 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, Protease Inhibitors*
ChIP Lysis Buffer #3: 10 mM Tris pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1% sodium
deoxycholate, 0.5% N-lauroylsarcosine, Protease Inhibitors*
Low-salt wash buffer: 20 mM Tris pH 8.1, 150 mM NaCl, 2 mM EDTA, 0.1% Sodium dodecyl sulfate
(SDS), 1% Triton X-100
High-salt wash buffer: 20 mM Tris pH 8.1, 500 mM NaCl, 2 mM EDTA, 0.1% SDS, 1% Triton X-100
LiCl salt wash buffer: 20 mM Tris pH 8.1, 0.25 M LiCl, 1 mM EDTA, 1% NP-40, 1% sodium
deoxycholate
TE: 10 mM Tris pH 8.0, 1 mM EDTA
Elution buffer: 10 mM Tris pH 8.0, 300 mM NaCl, 1 mM EDTA, 1% SDS
*Complete Mini EDTA-free protease inhibitor cocktail (Roche, Basel, Switzerland)
Antibody amounts per 1 ml IP: anti-ATF4 (sc-200): 5 μg, anti-ATF4 (D4B8): 1.06 μg, anti-ATF4
(ABE387): 20 μg, Rabbit IgG control: 5 μg
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RNA-Seq
Total RNA was purified with RNAzol RT (Sigma–Aldrich) according to the manufacturer’s
instructions. For RBM4 KO samples, equal amounts of total RNA were pooled from 4 independent
RBM4 KO cell clones. For ATF4 KO samples, equal amounts of total RNA were pooled from three
independent ATF4 KO cell clones. RNA-Seq libraries were prepared using the NEBNext Ultra
Directional RNA Library Prep Kit (New England BioLabs), including poly(A) selection using the
NEBNext Poly(A) mRNA Magnetic Isolation module. Library quality assessment and clustering were
performed as described for ChIP-Seq. Paired-end sequencing was performed using a GAIIx
Genome Analyzer (Illumina).
RNA-Seq reads were aligned using Tophat version 2.0.11 (Kim et al., 2013) using the reference
human genome hg19 and the reference transcriptome CRCh37.59 using the following options:
–library-type fr-firststrand –no-coverage-search –mate-inner-dist 300
Guided transcriptome reconstruction was done with Cufflinks Version 2.2.1 (Trapnell et al., 2012).
Cufflinks was run on the Tophat output file ‘accepted_hits.bam’ for each sample, using the hg19
reference genome and transcript annotation files and the options
-b hg19_ucsc.fa -M hg19.rRNA.gtf -g hg19_ucsc.refGene.gtf -u –min-frags-per-transfrag
After assembly was complete for each sample, the assembled transcripts were merged together
using Cuffmerge with the command template:
cuffmerge -o combined/ –min-isoform-fraction 0 -s hg19 assembly_list.txt
The merged transcriptome was compared against the reference transcriptome using Cuffcompare:
cuffcompare -r hg19_ucsc.refGene.gtf -s hg19 -R -M merged.gtf
This produced comparative statistics, and most importantly for this pipeline, a ‘.tmap’ file that lists
the most closely matching reference transcript for each of the assembled transcripts from merged.gtf.
The merged transcriptome was converted to genePred format (.gp) using the UCSC binary utility,
gtfToGenePred using the command:
gtfToGenePred merged.gtf merged.gp
merged.gp was joined to the .tmap file produced by Cuffcompare above, to obtain a transcriptome
file that is annotated with transcript IDs, exonic coordinates, gene IDs, and short-names of the most
closely matching reference transcripts. The Tophat output files ‘accepted_hits.bam’ for each sample
were sorted and converted to BED format using the BEDTools-2.17.0 utility bamToBed with the
command:
bamToBed -split -i accepted_hits.bam|sort -k1,1 -k2,2n -k3,3n > accepted_hits.bed
An executable (written in-house) called kcGEXM (Escobar et al., 2014) was used to obtain
normalized read counts and calculate reads per kilobase per million (RPKM) for transcripts. kcGEXM
uses the genePred and BED files as input:
kcGEXM -f gp -r merged.tmap.gp accepted_hits.bed > sample_name.cnt
where -f precedes the format of the reference annotation file and -r precedes the reference
annotation file.
In Figure 5—figure supplement 1, read densities were normalized to the total number of aligned
reads in a sample using Bedtools version 2.17.0 (Quinlan and Hall, 2010), and data were visualized
with IGV version 2.3.47 (Robinson et al., 2011). Sashimi plots were generated using MISO version
0.5.2 (Katz et al., 2010) with Python version 2.7.

Luciferase reporter assay
Fragments of the ULBP1 promoter were amplified from HAP1 genomic DNA and inserted into the pGL3Basic luciferase expression vector (Promega, Fitchburg, WI) between the KpnI and HindIII restriction
sites. Mutant ULBP1 promoter fragments were ordered from IDT (Coralville, IA). The sequences of the
ULBP1 promoter constructs can be found in Supplementary files 2–7. ATF4-mutant HAP1 cells were
plated at 10,000 cells/well in 96-well plates. 24 hr after plating, cells were co-transfected with the
indicated ULBP1 promoter constructs (99 ng), pRK5-FLAG-ATF4 or control vector (199 ng), and renilla
luciferase vector pRL-SV40 (1 ng). 24 hr post-transfection, cells were washed twice in PBS and lysed with
50 μl of passive lysis buffer (Promega #E1941). 15 μl of lysate was transferred to an opaque 96-well assay
plate. 100 μl of D-Luciferin reagent (synthesized in-house) was added to the lysates and samples
were immediately assessed for luminescence over a 10-s time period using an LMAX-II luminometer
(Molecular Devices, Sunnyvale, CA).
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